http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 12 Aug 2026 14:38:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Salmon+Sean/26912048.html si-local-file:///var/storage/secattach/20260812/26912048.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Salmon+Sean/26912048.html Wed, 12 Aug 2026 14:38:00 -0400 ADGM O.49933047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Salmon+Sean/26912048.html si-local-file:///var/storage/secattach/20260812/26912048.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Salmon+Sean/26912048.html Wed, 12 Aug 2026 14:38:00 -0400 ADGM O.49933047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Mirsaeedi-Farahani+Keyvan/26911857.html si-local-file:///var/storage/secattach/20260812/26911857.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Mirsaeedi-Farahani+Keyvan/26911857.html Wed, 12 Aug 2026 13:59:00 -0400 ADGM O.49933047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Mirsaeedi-Farahani+Keyvan/26911857.html si-local-file:///var/storage/secattach/20260812/26911857.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Mirsaeedi-Farahani+Keyvan/26911857.html Wed, 12 Aug 2026 13:59:00 -0400 ADGM O.49933047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Cox+James+L/26911815.html si-local-file:///var/storage/secattach/20260812/26911815.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Cox+James+L/26911815.html Wed, 12 Aug 2026 13:47:00 -0400 ADGM O.49933047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Cox+James+L/26911815.html si-local-file:///var/storage/secattach/20260812/26911815.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Cox+James+L/26911815.html Wed, 12 Aug 2026 13:47:00 -0400 ADGM O.49933047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+GARDINER+SANDRA+A./26911788.html si-local-file:///var/storage/secattach/20260812/26911788.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+GARDINER+SANDRA+A./26911788.html Wed, 12 Aug 2026 13:41:00 -0400 ADGM O.49933047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+GARDINER+SANDRA+A./26911788.html si-local-file:///var/storage/secattach/20260812/26911788.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+GARDINER+SANDRA+A./26911788.html Wed, 12 Aug 2026 13:41:00 -0400 ADGM O.49933047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+MISHAN+ORLY/26911768.html si-local-file:///var/storage/secattach/20260812/26911768.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+MISHAN+ORLY/26911768.html Wed, 12 Aug 2026 13:36:00 -0400 ADGM O.49933047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+MISHAN+ORLY/26911768.html si-local-file:///var/storage/secattach/20260812/26911768.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+MISHAN+ORLY/26911768.html Wed, 12 Aug 2026 13:36:00 -0400 ADGM O.49933047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Moran+Timothy+P./26911713.html si-local-file:///var/storage/secattach/20260812/26911713.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Moran+Timothy+P./26911713.html Wed, 12 Aug 2026 13:31:00 -0400 ADGM O.49933047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Moran+Timothy+P./26911713.html si-local-file:///var/storage/secattach/20260812/26911713.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Adagio+Medical+Holdings%2C++For%3A+Jun+16++Filed+by%3A+Moran+Timothy+P./26911713.html Wed, 12 Aug 2026 13:31:00 -0400 ADGM O.49933047 http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html <p> LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b>Recent Business Highlights:</b> </p><ul class="bwlistdisc"> <li> Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ <i>Ultra</i> Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) </li> </ul><ul http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html Tue, 11 Aug 2026 08:30:00 -0400 A.03607790 A.06822034 A.10745066 A.32635824 ADGM O.02054126 O.20026344 O.20147506 O.21503249 O.26228129 O.49933047 http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html <p> LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b>Recent Business Highlights:</b> </p><ul class="bwlistdisc"> <li> Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ <i>Ultra</i> Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) </li> </ul><ul http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html Tue, 11 Aug 2026 08:30:00 -0400 A.03607790 A.06822034 A.10745066 A.32635824 ADGM O.02054126 O.20026344 O.20147506 O.21503249 O.26228129 O.49933047 http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html <p> LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b>Recent Business Highlights:</b> </p><ul class="bwlistdisc"> <li> Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ <i>Ultra</i> Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) </li> </ul><ul http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html Tue, 11 Aug 2026 08:30:00 -0400 A.03607790 A.06822034 A.10745066 A.32635824 ADGM O.02054126 O.20026344 O.20147506 O.21503249 O.26228129 O.49933047 http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html <p> LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b>Recent Business Highlights:</b> </p><ul class="bwlistdisc"> <li> Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ <i>Ultra</i> Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) </li> </ul><ul http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html Tue, 11 Aug 2026 08:30:00 -0400 A.03607790 A.06822034 A.10745066 A.32635824 ADGM O.02054126 O.20026344 O.20147506 O.21503249 O.26228129 O.49933047 http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html <p> LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b>Recent Business Highlights:</b> </p><ul class="bwlistdisc"> <li> Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ <i>Ultra</i> Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) </li> </ul><ul http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html Tue, 11 Aug 2026 08:30:00 -0400 A.03607790 A.06822034 A.10745066 A.32635824 ADGM O.02054126 O.20026344 O.20147506 O.21503249 O.26228129 O.49933047 http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html <p> LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b>Recent Business Highlights:</b> </p><ul class="bwlistdisc"> <li> Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ <i>Ultra</i> Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) </li> </ul><ul http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html Tue, 11 Aug 2026 08:30:00 -0400 A.03607790 A.06822034 A.10745066 A.32635824 ADGM O.02054126 O.20026344 O.20147506 O.21503249 O.26228129 O.49933047 http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html <p> LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b>Recent Business Highlights:</b> </p><ul class="bwlistdisc"> <li> Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ <i>Ultra</i> Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) </li> </ul><ul http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html Tue, 11 Aug 2026 08:30:00 -0400 A.03607790 A.06822034 A.10745066 A.32635824 ADGM O.02054126 O.20026344 O.20147506 O.21503249 O.26228129 O.49933047 http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html <p> LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b>Recent Business Highlights:</b> </p><ul class="bwlistdisc"> <li> Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ <i>Ultra</i> Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) </li> </ul><ul http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html Tue, 11 Aug 2026 08:30:00 -0400 A.03607790 A.06822034 A.10745066 A.32635824 ADGM O.02054126 O.20026344 O.20147506 O.21503249 O.26228129 O.49933047 http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html <p> LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b>Recent Business Highlights:</b> </p><ul class="bwlistdisc"> <li> Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ <i>Ultra</i> Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) </li> </ul><ul http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html Tue, 11 Aug 2026 08:30:00 -0400 A.03607790 A.06822034 A.10745066 A.32635824 ADGM O.02054126 O.20026344 O.20147506 O.21503249 O.26228129 O.49933047 http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html <p> LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b>Recent Business Highlights:</b> </p><ul class="bwlistdisc"> <li> Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ <i>Ultra</i> Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) </li> </ul><ul http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html Tue, 11 Aug 2026 08:30:00 -0400 A.03607790 A.06822034 A.10745066 A.32635824 ADGM O.02054126 O.20026344 O.20147506 O.21503249 O.26228129 O.49933047 http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html <p> LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b>Recent Business Highlights:</b> </p><ul class="bwlistdisc"> <li> Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ <i>Ultra</i> Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) </li> </ul><ul http://www.streetinsider.com/Press+Releases/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html Tue, 11 Aug 2026 08:30:00 -0400 A.03607790 A.06822034 A.10745066 A.32635824 ADGM O.02054126 O.20026344 O.20147506 O.21503249 O.26228129 O.49933047 http://www.streetinsider.com/Business+Wire/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html <p> LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b>Recent Business Highlights:</b> </p><ul class="bwlistdisc"> <li> Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ <i>Ultra</i> Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) </li> </ul><ul http://www.streetinsider.com/Business+Wire/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html Tue, 11 Aug 2026 08:30:00 -0400 A.03607790 A.06822034 A.10745066 A.32635824 ADGM O.02054126 O.20026344 O.20147506 O.21503249 O.26228129 O.49933047 http://www.streetinsider.com/Business+Wire/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html <p> LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. </p><p> <b>Recent Business Highlights:</b> </p><ul class="bwlistdisc"> <li> Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ <i>Ultra</i> Ultra-Low temperature ablation catheter (“ULTA”), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”) </li> </ul><ul http://www.streetinsider.com/Business+Wire/Adagio+Medical+Reports+Second+Quarter+2026+Results/26902045.html Tue, 11 Aug 2026 08:30:00 -0400 A.03607790 A.06822034 A.10745066 A.32635824 ADGM O.02054126 O.20026344 O.20147506 O.21503249 O.26228129 O.49933047